Ton is an MD PhD, who led a biotech turnaround, with a new strategic plan, and financing. He completed six licensing and M&A transactions with over $1B in cumulative value. As head of R&D at specialty pharma companies, he achieved clinical and regulatory milestones, incl. a Special Protocol Assessment with FDA, pivotal studies, and sNDA approvals. Product development, marketing, and leadership experience at Novartis in Europe and Merck in the US.

Bob is both a CPA and corporate lawyer with extensive international experience in technology transfer, licensing, collaborative research and clinical trial agreements and mergers and acquisitions, most recently at Abbott Laboratories. As General Counsel for BASF Bioresearch, Bob was a key player in acquiring, protecting and developing Knoll’s drug HUMIRA®, and orchestrated the $6.9 Billion acquisition of Knoll AG by Abbott.